These results support the potential role of the PI3K/AKT/mTOR signaling in controlling de novo lipogenesis in HER2-positive breast cancer cells and show that PI3K inhibitors can decrease MUFAs production by inhibiting SCD-1 expression. Here, PIK3CA is linked to breast cancer.